Inhibikase Restructures RA Capital Stake: 18M Shares Exchanged for Pre-Funded Warrant

summarizeSummary

RA Capital exchanged 18.03 million common shares for a pre-funded warrant to acquire the same number of shares at $0.001, immediately reducing outstanding shares while preserving RA Capital's economic interest.

check_boxKey Events · Financing and Capital Events · IKT

• 18M Share Exchange for Pre-Funded Warrant

  RA Capital exchanged 18,030,000 common shares for a pre-funded warrant to acquire 18,030,000 shares at $0.001 per share, immediately exercisable with no expiration.

• Immediate Reduction in Outstanding Shares

  The exchange removes 18.03 million shares from the outstanding count, reducing the float and potentially increasing earnings per share, while RA Capital retains full economic exposure via the warrant.

• Beneficial Ownership Blocker at 9.99%

  The warrant includes a 9.99% beneficial ownership limitation, preventing RA Capital from exercising if it would exceed that threshold, with the option to increase to 19.99% upon 61 days' notice.

• No New Capital Raised

  This is a restructuring of an existing stake, not a new financing; no proceeds were received by the company in connection with the exchange.

auto_awesomeAnalysis · IKT · Life Sciences

RA Capital swapped 18.03 million common shares for a pre-funded warrant covering the same number of shares, exercisable at $0.001. This removes 18 million shares from the outstanding count immediately, reducing the float and potentially boosting EPS metrics, while RA Capital retains full economic exposure through the warrant. The warrant has no expiration and a 9.99% beneficial ownership blocker, so RA Capital cannot exercise if it would exceed that threshold. The transaction is a non-dilutive restructuring of an existing large stake, not a new capital raise, but it signals continued alignment between the company and its largest investor.